HRMY
Harmony Biosciences Holdings, Inc.
Biotechnology
Market Cap$1.89B
5Y Perf.-7.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
HRMY vs JAZZ
Revenue, margins, valuation, and 5-year total return — side by side.
JAZZ
Jazz Pharmaceuticals plc
Biotechnology
Market Cap$14.34B
5Y Perf.+70.1%
HRMY vs JAZZ — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | HRMY | JAZZ |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1.89B | $14.34B |
| Revenue (TTM) | $868M | $4.44B |
| Net Income (TTM) | $159M | $29M |
| Gross Margin | 77.2% | 66.9% |
| Operating Margin | 24.0% | 13.9% |
| Forward P/E | 9.3x | 9.5x |
| Total Debt | $20M | $5.42B |
| Cash & Equiv. | $753M | $1.39B |
HRMY vs JAZZ — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
HRMY
JAZZ
| Stock | Aug 20 | May 26 | Return |
|---|---|---|---|
| Harmony Biosciences… (HRMY) | 100 | 92.5 | -7.5% |
| Jazz Pharmaceutical… (JAZZ) | 100 | 170.1 | +70.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: HRMY vs JAZZ
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: HRMY leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Jazz Pharmaceuticals plc is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
HRMY
Harmony Biosciences Holdings, Inc.
The Growth Play
HRMY carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.
- Rev growth 21.5%, EPS growth 8.0%, 3Y rev CAGR 25.6%
- Lower volatility, beta 0.79, Low D/E 2.3%, current ratio 3.60x
- 21.5% revenue growth vs JAZZ's 4.9%
Best for: growth exposure and sleep-well-at-night
JAZZ
Jazz Pharmaceuticals plc
The Income Pick
JAZZ is the clearest fit if your priority is income & stability and long-term compounding.
- beta 0.65
- 58.3% 10Y total return vs HRMY's -11.4%
- Beta 0.65, current ratio 1.86x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | HRMY | 21.5% revenue growth vs JAZZ's 4.9% |
| Value | HRMY | Lower P/E (9.3x vs 9.5x) |
| Quality / Margins | HRMY | 18.3% margin vs JAZZ's 0.7% |
| Stability / Safety | JAZZ | Beta 0.65 vs HRMY's 0.79 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | JAZZ | +105.6% vs HRMY's +2.3% |
| Efficiency (ROA) | HRMY | 12.5% ROA vs JAZZ's 0.3%, ROIC 59.5% vs 2.1% |
HRMY vs JAZZ — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
HRMY vs JAZZ — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLHRMYLAGGINGJAZZ
JAZZJazz Pharmaceuticals …
2leads
HRMYHarmony Biosciences H…
3leads
6 Total Categories
CATEGORYLEADERvs JAZZMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
HRMY5/6
Valuation MetricsMultiples, price ratios, and targets
HRMY5/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
HRMY8/8
Total Returns1Y, 3Y, 5Y total returns with dividends
JAZZ6/6
Risk & VolatilityBeta, volatility, and downside exposure
JAZZ2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
HRMY leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JAZZ is the larger business by revenue, generating $4.4B annually — 5.1x HRMY's $868M. HRMY is the more profitable business, keeping 18.3% of every revenue dollar as net income compared to JAZZ's 0.7%.
| Metric | HRMYHarmony Bioscienc… | JAZZJazz Pharmaceutic… |
|---|---|---|
| RevenueTrailing 12 months | $868M | $4.4B |
| EBITDAEarnings before interest/tax | $232M | $994M |
| Net IncomeAfter-tax profit | $159M | $29M |
| Free Cash FlowCash after capex | $0 | $1.2B |
| Gross MarginGross profit ÷ Revenue | +77.2% | +66.9% |
| Operating MarginEBIT ÷ Revenue | +24.0% | +13.9% |
| Net MarginNet income ÷ Revenue | +18.3% | +0.7% |
| FCF MarginFCF ÷ Revenue | +40.1% | +28.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +21.1% | +19.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -55.3% | +3.9% |
HRMY leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
HRMY leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, HRMY's 5.0x EV/EBITDA is more attractive than JAZZ's 24.0x.
| Metric | HRMYHarmony Bioscienc… | JAZZJazz Pharmaceutic… |
|---|---|---|
| Market CapShares × price | $1.9B | $14.3B |
| Enterprise ValueMkt cap + debt − cash | $1.2B | $18.4B |
| Trailing P/EPrice ÷ TTM EPS | 12.10x | -39.14x |
| Forward P/EPrice ÷ next-FY EPS est. | 9.34x | 9.45x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 4.99x | 23.97x |
| Price / SalesMarket cap ÷ Revenue | 2.18x | 3.36x |
| Price / BookPrice ÷ Book value/share | 2.21x | 3.23x |
| Price / FCFMarket cap ÷ FCF | 5.44x | 11.06x |
HRMY leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
HRMY leads this category, winning 8 of 8 comparable metrics.
Profitability & Efficiency
HRMY delivers a 18.2% return on equity — every $100 of shareholder capital generates $18 in annual profit, vs $1 for JAZZ. HRMY carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to JAZZ's 1.26x.
| Metric | HRMYHarmony Bioscienc… | JAZZJazz Pharmaceutic… |
|---|---|---|
| ROE (TTM)Return on equity | +18.2% | +0.7% |
| ROA (TTM)Return on assets | +12.5% | +0.3% |
| ROICReturn on invested capital | +59.5% | +2.1% |
| ROCEReturn on capital employed | +22.6% | +2.2% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 |
| Debt / EquityFinancial leverage | 0.02x | 1.26x |
| Net DebtTotal debt minus cash | -$733M | $4.0B |
| Cash & Equiv.Liquid assets | $753M | $1.4B |
| Total DebtShort + long-term debt | $20M | $5.4B |
| Interest CoverageEBIT ÷ Interest expense | 15.43x | -3.72x |
HRMY leads this category, winning 8 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
JAZZ leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JAZZ five years ago would be worth $13,224 today (with dividends reinvested), compared to $11,959 for HRMY. Over the past 12 months, JAZZ leads with a +105.6% total return vs HRMY's +2.3%. The 3-year compound annual growth rate (CAGR) favors JAZZ at 18.1% vs HRMY's -3.1% — a key indicator of consistent wealth creation.
| Metric | HRMYHarmony Bioscienc… | JAZZJazz Pharmaceutic… |
|---|---|---|
| YTD ReturnYear-to-date | -12.3% | +32.0% |
| 1-Year ReturnPast 12 months | +2.3% | +105.6% |
| 3-Year ReturnCumulative with dividends | -9.1% | +64.8% |
| 5-Year ReturnCumulative with dividends | +19.6% | +32.2% |
| 10-Year ReturnCumulative with dividends | -11.4% | +58.3% |
| CAGR (3Y)Annualised 3-year return | -3.1% | +18.1% |
JAZZ leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
JAZZ leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
JAZZ is the less volatile stock with a 0.65 beta — it tends to amplify market swings less than HRMY's 0.79 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JAZZ currently trades 99.2% from its 52-week high vs HRMY's 80.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | HRMYHarmony Bioscienc… | JAZZJazz Pharmaceutic… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.79x | 0.65x |
| 52-Week HighHighest price in past year | $40.87 | $230.40 |
| 52-Week LowLowest price in past year | $25.52 | $97.50 |
| % of 52W HighCurrent price vs 52-week peak | +80.2% | +99.2% |
| RSI (14)Momentum oscillator 0–100 | 65.3 | 67.7 |
| Avg Volume (50D)Average daily shares traded | 776K | 956K |
JAZZ leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates HRMY as "Buy" and JAZZ as "Buy". Consensus price targets imply 42.8% upside for HRMY (target: $47) vs -5.4% for JAZZ (target: $216).
| Metric | HRMYHarmony Bioscienc… | JAZZJazz Pharmaceutic… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $46.80 | $216.14 |
| # AnalystsCovering analysts | 13 | 48 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.9% |
Insufficient data to determine a leader in this category.
Key Takeaway
HRMY leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). JAZZ leads in 2 (Total Returns, Risk & Volatility).
Best OverallHarmony Biosciences Holding… (HRMY)Leads 3 of 6 categories
Loading custom metrics...
HRMY vs JAZZ: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is HRMY or JAZZ a better buy right now?
For growth investors, Harmony Biosciences Holdings, Inc.
(HRMY) is the stronger pick with 21. 5% revenue growth year-over-year, versus 4. 9% for Jazz Pharmaceuticals plc (JAZZ). Harmony Biosciences Holdings, Inc. (HRMY) offers the better valuation at 12. 1x trailing P/E (9. 3x forward), making it the more compelling value choice. Analysts rate Harmony Biosciences Holdings, Inc. (HRMY) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — HRMY or JAZZ?
On forward P/E, Harmony Biosciences Holdings, Inc.
is actually cheaper at 9. 3x.
03Which is the better long-term investment — HRMY or JAZZ?
Over the past 5 years, Jazz Pharmaceuticals plc (JAZZ) delivered a total return of +32.
2%, compared to +19. 6% for Harmony Biosciences Holdings, Inc. (HRMY). Over 10 years, the gap is even starker: JAZZ returned +58. 3% versus HRMY's -11. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — HRMY or JAZZ?
By beta (market sensitivity over 5 years), Jazz Pharmaceuticals plc (JAZZ) is the lower-risk stock at 0.
65β versus Harmony Biosciences Holdings, Inc. 's 0. 79β — meaning HRMY is approximately 22% more volatile than JAZZ relative to the S&P 500. On balance sheet safety, Harmony Biosciences Holdings, Inc. (HRMY) carries a lower debt/equity ratio of 2% versus 126% for Jazz Pharmaceuticals plc — giving it more financial flexibility in a downturn.
05Which is growing faster — HRMY or JAZZ?
By revenue growth (latest reported year), Harmony Biosciences Holdings, Inc.
(HRMY) is pulling ahead at 21. 5% versus 4. 9% for Jazz Pharmaceuticals plc (JAZZ). On earnings-per-share growth, the picture is similar: Harmony Biosciences Holdings, Inc. grew EPS 8. 0% year-over-year, compared to -167. 5% for Jazz Pharmaceuticals plc. Over a 3-year CAGR, HRMY leads at 25. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — HRMY or JAZZ?
Harmony Biosciences Holdings, Inc.
(HRMY) is the more profitable company, earning 18. 3% net margin versus -8. 3% for Jazz Pharmaceuticals plc — meaning it keeps 18. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HRMY leads at 24. 0% versus 5. 3% for JAZZ. At the gross margin level — before operating expenses — JAZZ leads at 88. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is HRMY or JAZZ more undervalued right now?
On forward earnings alone, Harmony Biosciences Holdings, Inc.
(HRMY) trades at 9. 3x forward P/E versus 9. 5x for Jazz Pharmaceuticals plc — 0. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HRMY: 42. 8% to $46. 80.
08Which pays a better dividend — HRMY or JAZZ?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is HRMY or JAZZ better for a retirement portfolio?
For long-horizon retirement investors, Jazz Pharmaceuticals plc (JAZZ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
65)). Both have compounded well over 10 years (JAZZ: +58. 3%, HRMY: -11. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between HRMY and JAZZ?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: HRMY is a small-cap high-growth stock; JAZZ is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(HRMY: 21.1% · JAZZ: 19.1%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.